Abstract
Mycobacterium abscessus has emerged as a significant pulmonary pathogen characterized by its resistance to most first-line antimycobacterial drugs. Recent investigations have highlighted the clinical efficacy of including the oxazolidinone antibiotic linezolid in M. abscessus combination therapies, despite moderate resistance frequently being observed in patient isolates. Even with the potential usefulness of linezolid, the mechanisms that drive linezolid resistance in M. abscessus remain poorly understood. In several bacterial pathogens, including Mycobacterium tuberculosis, ATP-binding cassette (ABC) family proteins of the F subtype (ABC-F) have been found to confer antibiotic resistance to ribosome-targeting antibiotics, including linezolid. Here, we identified an M. abscessus ABC-F protein, MAB_2736c, that causes specific resistance to antibiotics that bind the 50S ribosomal subunit, including linezolid, macrolides, and chloramphenicol. These results demonstrate that targeting ABC-F proteins could help combat intrinsic resistance to several ribosome-targeting antibiotics in mycobacteria.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Antimicrobial Agents and Chemotherapy |
| Jahrgang | 70 |
| Ausgabenummer | 4 |
| ISSN | 0066-4804 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 04.2026 |
Fördermittel
T.F. was supported by a Boehringer Ingelheim Fonds MD fellowship. M.R.S. received support as a Merck Fellow of the Damon Runyon Cancer Research Foundation, DRG-2415-20. S.Z. was supported by award numbers T32GM145407, T32GM007753, and T32GM144273 from NIGMS and award number F30AI188797 from NIAID. E.J.R. was supported by NIH/NIAID under award number R01AI179642. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences, the National Institute of Allergy and Infectious Diseases, or the National Institutes of Health.
| Träger | Trägernummer |
|---|---|
| National Institute of Allergy and Infectious Diseases | |
| Boehringer Ingelheim Fonds | T32GM145407, T32GM007753, T32GM144273 |
| Damon Runyon Cancer Research Foundation | DRG-2415-20 |
| National Institutes of Health | R01AI179642 |
| National Institute of General Medical Sciences | F30AI188797 |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Fingerprint
Untersuchen Sie die Forschungsthemen von „Ribosomal protection as a linezolid resistance mechanism in Mycobacterium abscessus“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver